185 related articles for article (PubMed ID: 21912994)
1. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker.
Xiao MB; Jiang F; Ni WK; Chen BY; Lu CH; Li XY; Ni RZ
Med Oncol; 2012 Sep; 29(3):1886-91. PubMed ID: 21912994
[TBL] [Abstract][Full Text] [Related]
2. S100A11 is a potential prognostic marker for clear cell renal cell carcinoma.
Gabril M; Girgis H; Scorilas A; Rotondo F; Wala S; Bjarnason GA; Ding Q; Evans A; Tawedrous E; Pasic M; Finelli A; Al-Haddad S; Yousef GM
Clin Exp Metastasis; 2016 Jan; 33(1):63-71. PubMed ID: 26472670
[TBL] [Abstract][Full Text] [Related]
3. Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients.
Jiang N; Xue R; Bu F; Tong X; Qiang J; Liu R
Int J Clin Exp Pathol; 2014; 7(7):4120-7. PubMed ID: 25120791
[TBL] [Abstract][Full Text] [Related]
4. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
5. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker.
Hiraoka K; Hida Y; Miyamoto M; Oshikiri T; Suzuoki M; Nakakubo Y; Shinohara T; Itoh T; Shichinohe T; Kondo S; Kasahara N; Katoh H
Int J Cancer; 2002 May; 99(3):418-23. PubMed ID: 11992411
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
[TBL] [Abstract][Full Text] [Related]
7. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.
Streppel MM; Vincent A; Mukherjee R; Campbell NR; Chen SH; Konstantopoulos K; Goggins MG; Van Seuningen I; Maitra A; Montgomery EA
Hum Pathol; 2012 Oct; 43(10):1755-63. PubMed ID: 22542127
[TBL] [Abstract][Full Text] [Related]
8. High expression of TROP2 correlates with poor prognosis in pancreatic cancer.
Fong D; Moser P; Krammel C; Gostner JM; Margreiter R; Mitterer M; Gastl G; Spizzo G
Br J Cancer; 2008 Oct; 99(8):1290-5. PubMed ID: 18813308
[TBL] [Abstract][Full Text] [Related]
9. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
Patsouras D; Papaxoinis K; Kostakis A; Safioleas MC; Lazaris AC; Nicolopoulou-Stamati P
Mol Med Rep; 2015 Jun; 11(6):4585-90. PubMed ID: 25625587
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
14. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
15. Expression of Coiled-Coil Domain Containing 34 (CCDC34) and its Prognostic Significance in Pancreatic Adenocarcinoma.
Qi W; Shao F; Huang Q
Med Sci Monit; 2017 Dec; 23():6012-6018. PubMed ID: 29257799
[TBL] [Abstract][Full Text] [Related]
16. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
[TBL] [Abstract][Full Text] [Related]
18. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
19. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
20. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
